CMO Doyle Mittie executes net sale of shares as stock reaches 52-week high, mixed purchase and sale activity across two trading days.
Doyle Mittie, Chief Medical Officer of Avalo Therapeutics, executed a series of paired purchases and sales across May 5–6, with total sales slightly exceeding total purchases, resulting in a net reduction of his holdings. The transactions occurred as the stock reached its 52-week peak, suggesting he took advantage of elevated valuations to trim his position. Notably, while the CMO added significantly to his holdings through purchases on May 6, he simultaneously liquidated a larger dollar value through a cascade of sales across multiple price levels on the same day, indicating a tactical rebalancing rather than unidirectional conviction. The company's financial fundamentals remain challenged—operating at a substantial loss with highly negative earnings—which provides context for why an executive might elect to de-risk his position even as the stock has appreciated sharply. Without track record or prior transaction history provided, this appears to be a prudent tactical exit for a C-suite officer: the stock is now at its highest point, and the insider chose that window to reduce exposure.